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Subtype BAbstract Human immunodeficiency virus (HIV)-1 epidemics in Asian countries are driven by
varying exposures. The epidemiology of the regional pandemic has been changing with the
spread of HIV-1 to lower-risk populations through sexual transmission. Common HIV-1 genotypes
include subtype B and circulating recombinant form (CRF) 01_AE. Our objective was to use HIV-1
genotypic data to better quantify local epidemics. TASER-M is a multicenter prospective cohort
of HIV-infected patients. Associations between HIV exposure, patient sex, country of sample
origin and HIV-1 genotype were evaluated by multivariate logistic regression. Phylogenetic
methods were used on genotypic data to investigate transmission relationships. A total of
1086 patients from Thailand, Hong Kong, Malaysia and the Philippines were included in analyses.
Proportions of male patients within countries varied (Thailand: 55.6%, Hong Kong: 86.1%,
Malaysia: 81.4%, Philippines: 93.8%; p < 0.001) as did HIV exposures (heterosexual contact:
Thailand: 85.7%, Hong Kong, 46.2%, Malaysia: 47.8%, Philippines: 25.0%; p< 0.001). After adjust-
ment, we found increased subtype B infection among men who have sex with men, relative to
heterosexual-reported exposures (odds ratioZ 2.4, p < 0.001). We further describe four trans-
mission clusters of eight to 15 treatment naı¨ve, predominantly symptomatic patients (two each
for subtype B and CRF01_AE). Risk-group subpopulations differed with respect to the infecting
HIV-1 genotype. Homosexual exposure patients had higher odds of being infected with subtype
B. Where HIV-1 genotypes circulate within countries or patient risk-groups, local monitoring of
genotype-specific transmissions may play a role in focusing public health prevention strategies.
Phylogenetic evaluations provide complementary information for surveillance andmonitoring of
viruses with high mutation rates such as HIV-1 and Ebola.
Copyright ª 2015, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Human immunodeficiency virus (HIV)-1 infections are
dominated by group M viruses which are classified into nine
different subtypes (AeD, FeH, J, K). Circulating recombi-
nant forms (CRFs) result from recombination between HIV-1
genotypes (subtypes or CRFs) within a dually infected person
[1]. The AsiaePacific, representing more than 60% of the
world’s population is second only to sub-Saharan Africa in
HIV-infection prevalence (5 million) and incidence (14%) [2].
In Asia, country-specific epidemics feature different HIV
genotypes and epidemics are of increasing viral diversity.
Common regional genotypes are subtypes B and C,
CRF01_AE and their recombinants. Cambodia, Myanmar,
Thailand and Vietnam have been historically dominated by
CRF01_AE, in China’s Special Administrative Region of Hong
Kong subtype B and CRF01_AE cocirculate, mainland China
infections include B/C recombinants and subtype B in-
fections are common in Japan [3]. Previously, we reported
on Asian patients who were predominantly infected with
CRF01_AE and subtype B [4]. Among patients for whom both
HIV-1 protease and reverse transcriptase genotypes were
determined, 6.4% were infected with discordant protease
and reverse transcriptase genotypes, consisting mainly of
subtype B and CRF01_AE components.
HIV genotype diversity is associated with the heteroge-
neity in the human subpopulations driving regional Asian
epidemics [5]. Sexual transmission accounts for most in-
fections globally. However, in the AsiaePacific, epidemics
are diverse with concentrated, generalized and low-
prevalence epidemics predominating in different coun-
tries. In many countries, epidemics have been historicallyconcentrated in high-risk groups such as people who inject
drugs (including street children), men who have sex with
men (MSM), sex workers, their clients, and sexual partners.
The epidemiology of the Asian pandemic is changing with
HIV-1 being increasingly spread to lower-risk populations
with onward sexual transmission to female partners of high-
risk groups helping to sustain generalized epidemics [5].
Phylogenetic analysis is a method of reconstructing re-
lationships between genotypic sequences and is one strat-
egy for studying viral transmission dynamics in humans.
Phylogenetic studies cannot determine the direction of
HIV-1 evolution or, consequently, the direction of trans-
mission [6]. Classification of like sequences into clusters
can, however, identify transmission networks thereby
helping to quantify the evolving roles of cocirculating ge-
notypes [7]. Although transmission network evaluations are
not routinely incorporated in incidence reporting.
Under the TREAT Asia Studies to Evaluate Resistance
monitoring (TASER-M) protocol [8], patient characteristics
are collected and infecting HIV-1 isolates are genotypically
sequenced. We used TASER-M baseline data to evaluate
associations between patient risk group and infecting ge-
notype. For additional context, we complemented findings
with descriptions of transmission clusters among our
patients.
Methods
Patients were enrolled in a multicenter, prospective cohort
[8]. Covariates included age at study entry, sex, patient-
reported HIV exposure, hepatitis B (HBV) and hepatitis C
(HCV) coinfections, and indices of illness severity [CD4 T
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Control and Prevention (CDC) classification] [9]. The most
severe pre-TASER-M CDC category was used as baseline
clinical status. HBV (HCV) positive status was defined as
having any HBsAg (HCV-Ab) positive result prior to enrol-
ment. Patients reporting dual HIV-exposure routes were
classified under the category of higher risk. For individual
country analyses, due to small numbers of patients
reporting injecting drug use (IDU), infection by blood
products or having unknown exposure, these modes of
infection were excluded.
For univariate comparisons by country, c2, Fisher’s exact
or KruskaleWallis tests were performed, as appropriate.
Associations between patient-reported HIV-exposure, sex,
country of isolate origin and infecting HIV-1 genotype
(subtype B or CRF01_AE) were evaluated by multivariate
logistic regression, for individual countries and overall.
Forward step-wise techniques were used to determine best
fitting models. Binary covariate and multicategorical
parameter p values < 0.2 (tests for trend/heterogeneity),
in univariate assessments, were considered for multivariate
models. Final multivariate models consisted of covariates
remaining significant at p < 0.05. Analyses were performed
using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).
Phylogenetic analysis was used to identify transmission
clusters among patients. Sequences not passing quality
control evaluations (Virco BVBA, Beerse, Belgium) or with
missing bases or gaps were excluded. By genotype,
remaining sequences were trimmed using Clustal W,
implemented in MEGA version 5 [10]. HXB2 and two
CRF01_AE reference strains (TH.90, TH93, http://www.hiv.
lanl.gov) were used to align subtype B and CRF01_AE se-
quences, respectively. Each reference strain set (B,
CRF01_AE) served as outgroup for the other.
Phylogenetic topologies were generated by HIV
Sequence Database PhyML (v2.4.4) using the method of
maximum likelihood and general time reversible (GTR) plus
gamma nucleotide substitution model, verified on the data
[11]. Subtype B sequences were analyzed as a group. Due to
resource limitations imposed by computations for the larger
number of CRF01_AE sequences, phylogenies were gener-
ated by country. For Thailand, sequences were further
separated into Bangkok metropolitan (Thai Metro) or
regional urban centers (Thai Urban: Chiang Mai, Chiang
Rai). Clustering was determined using bootstrapping with
an acceptable 100 replicates.Nucleotide sequence accession numbers
The HIV-1 sequences reported in this study have been
deposited in GenBank with accession numbers KC791222 to
KC791224, KC791226 to KC791228, KC791230 to KC791236,
KC791238 to KC791269, KC791271 to KC791285, KC791288
to KC791297, KC791299 to KC791314, KC791316 to
KC791344, KC791346 to KC791354, KC791356 to KC791363,
KC791365, KC791366, KC810320 to KC810322, KC810324,
KC810326 to KC810329, KC810331 to KC810386, KC810388
to KC810396, KC810398 to KC810410, KC810412 to
KC810424, KC810426 to KC810431, KC810433 to KC810487,
KC810489 to KC810501, KC810503 to KC810510, KC810512
to KC810517, KC810544 to KC810548, KC810550 toKC810557, KC810559 to KC810562, KC810564, KC810565,
KC810567 to KC810573, KC810575, KC810577 to KC810580,
KC810582 to KC810637, KC810639 to KC810647, KC810649
to KC810661, KC810663 to KC810675, KC810677 to
KC810682, KC810684 to KC810738, KC810740 to KC810752,
KC810754 to KC810761, KC810763 to KC810768, KC810795
to KC810799, KC810801 to KC810808, KC810810 to
KC810813, KC810815, KC810816, KC810818 to KC810821,
KC856945, KC856946, KC856947 to KC856950, KC856952 to
KC856960, to KC856980, KC856982, KC856983, KC856985 to
KC857009, KC857011 to KC857021, KC857023 to KC857029,
KC857031 to KC857042, KC857044 to KC857052, KC857054
to KC857056, KC857058 to KC857061, KC857063 to
KC857084, KC857105, KC857107 to KC857111, KC857113 to
KC857121, KC857123 to KC857141, KC857143, KC857144,
KC857146 to KC857170, KC857172 to KC857182, KC857184
to KC857190, KC857192 to KC857203, KC857205 to
KC857213, KC857215 to KC857217, KC857219 to KC857222,
KC857224 to KC857245, KC867560 to KC867616, KC867618
to KC867620, KC867622 to KC867647, KC921421, KC921422,
KC921767, KC921769 to KC921774, KC921776 to KC921783,
KC921787, KC921789 to KC921793, KC921795 to KC921797,
KC921799 to KC921805, KC921807 to KC921822, KC921827
to KC921829, KC921832, KC921834, KC921836 to KC921842,
KC921844 to KC921848, KC921850, KC921852 to KC921859,
KC921861 to KC921866, KC921868 to KC921872, KC921874
to KC921880, KC921882 to KC921887, KC921889 to
KC921896, KC921900, KC921902 to KC921906, KC921908 to
KC921910, KC921912 to KC921918, KC921920 to KC921935,
KC921940 to KC921942, KC921945, KC921947, KC921949 to
KC921955, KC921957 to KC921961, KC921963, KC921965 to
KC921972, KC921974 to KC921979, KC921981 to KC921985,
KC921987 to KC921992, KC970855 to KC970858, KC970861,
KC970862, KC970865, KC970869 to KC970871, KC970874,
KC970875, KC970878, KC970882, KC970890, KC970894,
KC970907, KC970909, KC970911, KC970914, KC970915,
KC970924 to KC970928, KC970931, KC970933, KC970936,
KC970938, KC970945 to KC970947, KC970949, KC970952,
KC970954, KC970958, KC970961, KC970964, KC970966,
KC970967, KC970970, KC970971, KC970976, KC970978,
KC970979, KC970982 to KC970985, KC970988, KC970989,
KC970992, KC970996, KC970998, KC970999, KC971002,
KC971003, KC971006 to KC971009, KC971012 to KC971014, ,
KC971023, KC971025, KC971028, KC971030, KC971033 to
KC971035, KC971041, KC994162 to KC994169, KC994171 to
KC994182, KC994184 to KC994186, KC994188 to KC994190,
KC994193 to KC994196, KC994198 to KC994202, KC994204
to KC994211, KC994213 to KC994220, KC994223 to
KC994225, KC994227 to KC994234, KC994236 to KC994241,
KC994243, KC994245, KC994247 to KC994249, KC994251 to
KC994260, KC994262 to KC994264, KC994267, KC994269,
KC994271 to KC994273, KC994275 to KC994279, KC994281,
KC994342 to KC994360, KC994362, KC994364 to KC994368,
KC994371 to KC994376, KC994379, KC994380, KC994383 to
KC994387, KC994451, KC994452, KF273871 to KF273901.Results
A total of 1086 patients enrolled between 2007 and 2010 from
nine clinic locations in Thailand (nZ 4), Hong Kong (China;
n Z 2) Malaysia (n Z 2), and the Philippines (n Z 1) were
448 R.A. Oyomopito et al.included. Excepting antiretroviral therapy experience, dif-
ferences existed for all covariates shown in Table 1. Hong
Kong patients were older (p < 0.001) and proportions of
males within countries varied (p < 0.001). Patients from
Thailandmore frequently reported exposure as heterosexual
contact (p < 0.001). Testing differed between countries for
HBV (p < 0.001) and HCV (p < 0.001). In the 95% of patients
naı¨ve to antiretroviral therapy, country differences wereTable 1 Patient characteristics by country.
Thailand Hong Kong
n Z 768 (70.7%) n Z 173 (15.9
Age (y),
Median (IQR) 36.7 (31.2e42.5) 41.3 (33.9e49.
Sex
Male 427 (55.6) 149 (86.1)
Female 341 (44.4) 24 (13.9)
Ethnicity
Caucasian 0 (0.0) 5 (2.9)
Chinese 0 (0.0) 152 (87.9)
Indian 0 (0.0) 0 (0.0)
Malay 0 (0.0) 0 (0.0)
Filipino 0 (0.0) 1 (0.6)
Thai 761 (99.1) 6 (3.5)
Other 7 (0.9) 9 (5.2)
HIV exposure
Homosexual contact 84 (10.9) 86 (49.7)
Homosexual & IDU 1 (0.1) 0 (0.0)
IDU only 4 (0.5) 1 (0.6)
Heterosexual contact 658 (85.7) 80 (46.2)
Heterosexual & IDU 11 (1.4) 1 (0.6)
Receipt of blood/products 2 (0.3) 1 (0.6)
Perinatal transmission 1 (0.1) 0 (0.0)
Unknown 7 (0.9) 4 (2.3)
Hepatitis B
Negative 452 (58.9) 144 (83.2)
Positive 54 (7.0) 17 (9.8)
Not tested 262 (34.1) 12 (6.9)
Hepatitis C
Negative 401 (52.2) 143 (82.7)
Positive 33 (4.3) 8 (4.6)
Not tested 334 (43.5) 22 (12.7)
ARV experience
Naı¨ve 722 (94.0) 168 (97.1)
First-line experienced 36 (4.7) 5 (2.9)
ARVs for MTCT 10 (1.3) 0 (0.0)
Baseline CD4 count (cells/mL)a
Median (IQR) 96 (35e195) 61 (19.5e173
Log10 HIV-1 viral load (copies/mL)
a
Median (IQR) 5 (4.6e5.3) 5.2 (4.9e5.6)
CDC classificationa
Category A 315 (43.6) 63 (37.5)
Category B 113 (15.7) 21 (12.5)
Category C 294 (40.7) 84 (50.0)
Data are presented as n (%), unless otherwise indicated.
ARV Z antiretroviral; CDC Z Centers for Disease Control and Prevent
use; IQR Z interquartile range; MTCT Z mother-to-child transmissio
a Country results for CDC class, baseline CD4 counts and HIV-1 RNA ar
HIV-1 viral load (CD4 counts) at baseline.found in CD4 counts (p < 0.001), log10 HIV-1 RNA copies/mL
(p < 0.001) and CDC classification (p < 0.001).
Of all genotypes, approximately 98% of patients were
infected with either CRF01_AE [nZ 882 (81.2%)] or subtype
B [n Z 178 (16.4%)]. Due to the small numbers of patients
from some countries, HIV exposure was restricted to het-
erosexual and homosexual contact in country-specific ana-
lyses. Adjusted estimates for Hong Kong patients,Malaysia Philippines Total
%) n Z 113 (10.4%) n Z 32 (2.9%) n Z 1086 (99.9%)
7) 35.7 (31.1e44.7) 34.3 (29e41.2) 36.8 (31.6e44.4)
92 (81.4) 30 (93.8) 698 (64.3)
21 (18.6) 388 35.7)
1 (0.9) 0 (0.0) 6 (0.6)
51 (45.1) 0 (0.0) 203 (18.7)
14 (12.4) 0 (0.0) 14 (1.3)
44 (38.9) 0 (0.0) 44 (4.1)
0 (0.0) 32 (100.0) 33 (3.0)
0 (0.0) 0 (0.0) 767 (70.6)
3 (2.7) 0 (0.0) 19 (1.7)
26 (23.0) 24 (75.0) 220 (20.3)
1 (0.9) 0 (0.0) 2 (0.2)
16 (14.2) 0 (0.0) 21 (1.9)
54 (47.8) 8 (25.0) 800 (73.7)
4 (3.5) 0 (0.0) 16 (1.5)
0 (0.0) 0 (0.0) 3 (0.3)
0 (0.0) 0 (0.0) 1 (0.1)
12 (10.6) 0 (0.0) 23 (2.1)
93 (82.3) 13 (40.6) 702 (64.6)
5 (4.4) 2 (6.3) 78 (7.2)
15 (13.3) 17 (53.1) 306 (28.2)
75 (66.4) 0 (0.0) 619 (57.0)
20 (17.7) 0 (0.0) 61 (5.6)
18 (15.9) 32 (100.0) 406 (37.4)
113 (100.0) 30 (93.8) 1033 (95.1)
0 (0.0) 2 (6.3) 43 (4.0)
0 (0.0) 0 (0.0) 10 (0.9)
.5) 153.5 (40e226) 227 (143e303) 97 (32e200)
5.1 (4.6e5.4) 5.2 (5e5.6) 5 (4.6e5.4)
96 (85.0) 18 (60.0) 492 (47.6)
0 (0.0) 2 (6.7) 136 (13.2)
17 (15.0) 10 (33.3) 405 (39.2)
ion; HIV Z human immunodeficiency virus; IDU Z injecting drug
n.
e for ARV-naı¨ve patients only. There were 18 (24) patients missing
Risk group characteristics and HIV-1 transmission 449suggested that homosexual contact had higher odds of
subtype B infection [odds ratio (OR) Z 3.1; p < 0.001]
whereas women had lower odds (ORZ 0.164; p < 0.023). In
Thailand patients, after adjustment for HIV exposure,
women had lower odds of subtype B infection (ORZ 0.396;
p < 0.008). In Malaysia, no associations were found,
possibly due to small cell sizes. There were insufficient data
from the Philippines to perform the analysis.
For logistic regression analyses including all countries,
patients having any IDU exposure were collapsed into one
category, Any IDU. Univariate and adjusted estimates for all
countries are shown in Table 2. After adjustment, females
had lower odds of subtype B infection (OR Z 0.4,
p < 0.003). The overall heterogeneity test p value must be
significant before category effects can be interpreted as
contributing and both HIV-exposure (p < 0.001) and country
(p < 0.001) were associated with infecting genotype. Pa-
tients reporting homosexual exposure had higher odds of
being infected with subtype B, compared with heterosexual
exposure (OR Z 2.4, p < 0.001). Compared with patients
from Thailand, patients from Hong Kong (OR Z 8.9,
p < 0.001), Malaysia (OR Z 3.6, p < 0.001), and the
Philippines (OR Z 10.4, p < 0.001) had higher odds of
subtype B infection.
Following quality control and sequence preparation,
there were 114 subtype B and 753 CRF01_AE sequences
from Thailand, Hong Kong, and Malaysia remaining for
phylogenetic reconstruction. Subtype B analysis was per-
formed on all sequences of this subtype, resulting in 15
groups [bootstrap value (BV) > 70%] comprising of clusters
of 15 and nine, two triplets and 11 pairs (Figure 1). The
cluster of 15 sequences (BVZ 99%) included men attending
two sites in Hong Kongdone patient reporting heterosexual
exposure, the others self-identifying as MSM [age in years:
median: 40.7, minimum: 20.8, maximum: 58.6;Table 2 Factors associated with subtype B infection
n No. U
Subtype B
n (%)
O
Patient covariates
Sex
Male 681 159 (23.3)
Female 379 19 (5.0) 0.
HIV exposure
Heterosexual contact 781 74 (9.5)
Homosexual contact 216 92 (42.6) 7.
Any IDU exposure 39 5 (12.8) 1.
Unknown 24 7 (29.2) 3.
Country
Thailand 763 51 (6.7)
Hong Kong, China 161 82 (50.9) 14.
Malaysia 109 28 (25.7) 4.
Philippines 27 17 (63.0) 23.
Total 1060 178 (16.8)
Reference categories for sex, HIV exposure, and country are male, h
exposure and country categories are test for homogeneity.
CI Z confidence interval; HIV Z human immunodeficiency virus; IDUsymptomatic (CDC C or B): n Z 11/15 (73.3%)]. The nine-
group cluster (BV Z 99%) were male patients from two
sites in Bangkok comprising of six patients reporting het-
erosexual contact and three MSM exposures [age in years:
median: 30.8, minimum: 26.5, maximum: 36.0; symptom-
atic: n Z 5/9 (55.6%)]. Malaysian clusters included a male
heterosexual/MSM pair, one each from two sites in Kuala
Lumpur (BV Z 100%). The only clustering female isolate
was similar to that of a male patient reporting unknown
exposure.
Due to the large number of sequences, CRF01_AE ana-
lyses were performed individually for Hong Kong, Malaysia,
Thai Metro, and Thai Urban. Ten groups were detected
among 70 patients from Hong Kong (Figure 2); a cluster of
10 [heterosexual; male: nZ 8, female: nZ 2; age in years:
median: 55.7, minimum: 34.2, maximum: 70.8; symptom-
atic: nZ 8/10 (80.0%), BVZ 98%)], a cluster of eight [MSM:
nZ 6, heterosexual female: nZ 1, male IDU: nZ 1; age in
years: median: 41.0, minimum: 26.0, maximum: 46.7;
symptomatic: nZ 5/8 (62.5%), BVZ 100%], and eight pairs
(BVs > 70%). There was a relatively small amount of clus-
tering found in collections of Thai Metro (n Z 288; pairs:
nZ 4, BVs  99%) or Thai Urban sequences (nZ 344; pairs:
nZ 9, triplets: nZ 1; BVs  70%). For the 51 isolates from
Malaysia (Figure 3), five clusters were found; two clusters
of four (BV > 91%), one including patients from two sites in
Kuala Lumpur, and one pair (BV Z 79%). A subset of 14
CRF01_AE sequences clustered closer to outgroup subtype B
and were verified using HIV Sequence Database BLAST
(http://www.hiv.lanl.gov). Of these, one pair and one
triplet included three IDU males (BV > 86%).
Overall for subtype B or CRF01_AE, patients in groups of
eight or more (n Z 42) were treatment-naı¨ve, aged 21e71
years [median: 39.8 years, interquartile range (IQR):
31.8e47.3], symptomatic [n Z 29/42 (69.1%)], with lownivariate analysis Multivariate analysis
R p OR (95% CI) p
17 < 0.001 0.43 (0.2e0.7) 0.003
< 0.001 < 0.001
09 < 0.001 2.37 (1.5e3.7) < 0.001
41 0.492 0.74 (0.3e2.1) 0.566
93 0.003 2.21 (0.8e6.1) 0.127
< 0.001 < 0.001
49 < 0.001 8.89 (5.7e13.9) < 0.001
83 < 0.001 3.63 (2.1e6.4) < 0.001
73 < 0.001 10.42 (4.3e25.2) < 0.001
eterosexual contact and Thailand respectively; p values for HIV
Z injecting drug use; OR Z odds ratio.
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Figure 1. Phylogenetic reconstructiondsubtype B sequences. Branches in red leading to groups of anonymous patient identifiers
show those groups of sequences with bootstrap statistics >80%. Clusters of 15 (Hong Kong, China) and nine (Bangkok, Thailand)
sequences are boxed in blue.
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Figure 2. CRF01_AE phylogenetic reconstructiondHong Kong. Branches in red leading to groups of anonymous patient identifiers
show those groups of sequences with bootstrap statistics >80%. Clusters of 15 and eight sequences are boxed in blue.
Risk group characteristics and HIV-1 transmission 451CD4 counts (median: 80 cells, IQR: 29e180), and high viral
load (median: 177,901 copies/mL, IQR: 84,000e406,100).Discussion
This large-scale study of HIV-1 genotypes in patients from
South-East Asia showed country-specific differences in HIV
epidemiology and increased subtype B infection among MSMpatients, relative to patients reporting heterosexual expo-
sures. Overall, one half of treatment-naı¨ve patients were
asymptomatic. By contrast, treatment-naı¨ve patients in
clusters of eight or more, were predominantly symptomatic
with enhanced capacity for onward transmission.
Our study limitations include that TASER-M was not
specifically designed to provide regional surveillance esti-
mates. Intermediary transmission events outside our cohort
are also unknown. Consequently, patients and networks
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Figure 3. CRF01_AE phylogenetic reconstructiondMalaysia. Branches in red leading to groups of anonymous patient identifiers
show those groups of sequences with bootstrap statistics >80%. Clusters are boxed in blue.
452 R.A. Oyomopito et al.cannot be considered entirely representative of countries
or the region. Computing restrictions possibly impacted the
precision of our phylogenetic estimates, however, the
methods are sufficiently robust to support interpretations.
Additional investigation of Malaysian sequences, including
those for people who inject drugs, is required. Malaysia is
an environment where extensive recombination is reported
and sequence variation may have reflected this [12].
Sequence preparation may have artifactually impacted on
interpretations. Nevertheless, with the large number of
contributing sequences, misclassification effects would be
small.
In Asia, drivers of country-level HIV-1 epidemics are
diverse [5] and our results show that different viral geno-
types can predominate in specific patient risk-groups. Local
prevention strategies need to target subpopulations at-risk
for regional reductions. HIV-1 genotype is routinely avail-
able from drug resistance testing. Therefore, infecting
HIV-1 genetic information from phylogenetic studies, part-
nered with assessment of de-identified patient character-
istics, could enhance local epidemic surveillance andmonitoring to better focus prevention efforts. Timely
reporting of changes in HIV-1 genotype distributions,
including entry of novel variants into local settings, could
inform public health strategies and help arrest proliferation
of HIV-1 clusters into transmission networks. Phylogenetic
assessments may be used to enhance tracking of HIV-1 and
other disease entities with high mutation rates, such as
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